Phenotype of TP53 and influence on outcome after allogeneic stem cell transplantation for myelofibrosis

被引：0
|
作者：
Gagelmann, N. [1 ]
Badbaran, A. [1 ]
Panagiota, V [2 ]
Thol, F. [2 ]
Heuser, M. [2 ]
Wolschke, C. [1 ]
Schroeder, T. [3 ]
Rautenberg, C. [3 ]
Reinhardt, H. C. [3 ]
Cassinat, B. [4 ]
Robin, M. [4 ]
Scott, B. L. [5 ]
Kroeger, N. [1 ]
机构：
[1] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany
[2] Hannover Med Sch, Hannover, Germany
[3] Univ Klinikum Essen, Essen, Germany
[4] Hop St Louis, APHP, Paris, France
[5] Fred Hutchinson Canc Res Ctr, Seattle, WA USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V295
引用
收藏
页码：80 / 80
页数：1
相关论文
共 50 条
  • [41] Outcome of allogeneic stem cell transplantation in patients with idiopathic myelofibrosis: The GITMO experience
    Patriarca, F.
    Sperotto, A.
    Van Lint, M. T.
    Porretto, F.
    Di Bartolomeo, P.
    Iori, A. P.
    Visani, G.
    Bacigalupo, A.
    Bosi, A.
    Fanin, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 2 - 3
  • [42] Outcome of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia
    Ditschkowski, M
    Elmaagacli, AH
    Trenschel, R
    Thiele, J
    Beelen, DW
    BONE MARROW TRANSPLANTATION, 2003, 31 : S108 - S109
  • [43] Double, double, TP53, and trouble in myelofibrosis
    Krishnamurthy, Pramila
    BLOOD, 2023, 141 (23) : 2793 - 2795
  • [44] IMPACT OF MOLECULAR REMISSION ON CLINICAL OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN 14 PATIENTS WITH MYELOFIBROSIS
    Casetti, I. C.
    Cavalloni, C.
    Rumi, E.
    Pietra, D.
    Sant'Antonio, E.
    Bellini, M.
    Milanesi, C.
    Ferretti, V.
    Boveri, E.
    Pascutto, C.
    Astori, C.
    Ripamonti, F.
    Della Porta, M.
    Caldera, D.
    Colombo, A. A.
    Bernasconi, P.
    Alessandrino, E. P.
    Cazzola, M.
    HAEMATOLOGICA, 2014, 99 : 667 - 667
  • [45] TP53 mutations and Polymorphisms in Primary Myelofibrosis
    Raza, Sania S.
    Viswanatha, David
    Erickson, Lori A.
    Lasho, Terra L.
    Finke, Christy
    Knudson, Ryan A.
    Ketterling, Rhett
    Pardanani, Animesh D.
    Tefferi, Ayalew
    BLOOD, 2011, 118 (21) : 1641 - 1641
  • [46] TP53 mutation is rare in primary myelofibrosis
    Greaves, Wesley O.
    Verma, Shalini
    Bisrat, Tigist
    Strati, Paolo
    Rahimi, Hamed
    Paladugu, Abhaya V.
    Luthra, Rajyalakshmi
    Patel, Keyur P.
    Medeiros, L. Jeff Rey
    Yao, Hui
    Pierce, Sherry
    Bueso-Ramos, Carlos E.
    Verstovsek, Srdan
    LEUKEMIA & LYMPHOMA, 2013, 54 (07) : 1552 - 1552
  • [47] Impact of pre-transplant ruxolitinib in myelofibrosis patients on outcome after allogeneic stem cell transplantation
    Abd Kadir, Syed
    Shahnaz, Sharifah
    Zabelina, Tatjana
    Christopeit, Maximilian
    Wulf, Gerald
    Wagner, Eva
    Bornhaeuser, Martin
    Schroeder, Thomas
    Crysandt, Martina
    Mayer, Karin Tina
    Stelljes, Matthias
    Badbaran, Anita
    Wolschke, Christine
    Ayuketang, Ayuk Francis
    Triviai, Ioanna
    Wolf, Dominik
    Kroeger, Nicolaus
    BONE MARROW TRANSPLANTATION, 2017, 52 : S423 - S423
  • [48] Impact of Pre-Transplant Ruxolitinib in Myelofibrosis Patients on Outcome after Allogeneic Stem Cell Transplantation
    Abd Kadir, Sharifah Shahnaz Syed
    Zabelina, Tatjana
    Christopeit, Maximilian
    Wulf, Gerald G.
    Wagner, Eva Maria
    Bornhaeuser, Martin
    Schroeder, Thomas
    Crysandt, Martina
    Mayer, Karin
    Stelljes, Matthias
    Badbaran, Anita
    Wolschke, Christine
    Ayuk, Francis A.
    Triviai, Ioanna N.
    Wolf, Dominik
    Kroeger, Nicolaus
    BLOOD, 2016, 128 (22)
  • [49] Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes
    Wang, Wei
    Auer, Paul
    Zhang, Tao
    Spellman, Stephen
    Carlson, Karen-Sue
    Nazha, Aziz
    Bolon, Yung-Tsi
    Saber, Wael
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (08): : 659.e1 - 659.e6
  • [50] Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status
    Aldoss, Ibrahim
    Pham, Anh
    Li, Sierra Min
    Gendzekhadze, Ketevan
    Afkhami, Michelle
    Telatar, Milhan
    Hong, Hao
    Padeganeh, Abbas
    Bedell, Victoria
    Cao, Thai
    Khaled, Samer K.
    Al Malki, Monzr M.
    Salhotra, Amandeep
    Ali, Haris
    Aribi, Ahmed
    Palmer, Joycelynne
    Aoun, Patricia
    Spielberger, Ricardo
    Stein, Anthony S.
    Snyder, David
    O'Donnell, Margaret R.
    Murata-Collins, Joyce
    Senitzer, David
    Weisenburger, Dennis
    Forman, Stephen J.
    Pullarkat, Vinod
    Marcucci, Guido
    Pillai, Raju
    Nakamura, Ryotaro
    HAEMATOLOGICA, 2017, 102 (12) : 2030 - 2038
12345